Bryan Unger: 1st Patient Has Been Enrolled in NuvOx Therapeutics’ Phase IIb NOVEL Trial
Bryan Unger, Director of Business Development at Microvascular Therapeutics, reposted from NuvOx Therapeutics on LinkedIn:
”Proud to share that the first patient has been enrolled in NuvOx Therapeutics’ Phase IIb NOVEL trial evaluating NanO₂™ in acute ischemic stroke due to large vessel occlusion.
Stroke is one of the leading drivers of long-term disability and healthcare costs, with lifelong care representing a substantial burden for patients, families, and health systems.
Our Phase IIa data for NanO₂ showed strong potential in reducing this burden.
Reaching the first patient enrolled is a critical milestone.
We are grateful to the clinical teams and partners who are advancing this work.”
Quoting NuvOx Therapeutics‘s post:
”We have enrolled the first patient in NuvOx Therapeutics’ Phase IIb NOVEL trial evaluating NanO₂™ in acute ischemic stroke due to large vessel occlusion (LVO).
NOVEL is a multicenter, randomized, placebo-controlled study funded by the NIHR (National Institute for Health and Care Research)–MRC EME Programme, and co-sponsored by the University of Glasgow and NHS Greater Glasgow and Clyde.
This milestone advances NanO₂, designed to rapidly improve tissue oxygenation, toward addressing one of the most severe and costly forms of stroke.
We thank our clinical collaborators and funding partners as we activate additional sites and accelerate enrollment.”
Read the full announcement here.
Stay updated with Hemostasis Today.
-
Jun 23, 2026, 18:27Advancing Gene Therapy Research for Glanzmann Thrombasthenia – Glanzmann’s Research Foundation
-
Jun 23, 2026, 18:17What Every ITP Patient Wants to Know – ITP Support Association
-
Jun 23, 2026, 18:13Ahsan Fareed: Exploring Heart Failure Readmissions in Iron Deficiency Anemia
-
Jun 23, 2026, 18:09Swarnava Roy: Key Findings on Stress Erythropoiesis and Mitochondrial Retention in RBCs
-
Jun 23, 2026, 17:40Hossam El Benawi: How do We Predict Recurrence Post LVT Resoultion?
-
Jun 23, 2026, 17:39Nicolas Gendron: Do We Really Need All These Hemostasis Tests in Patients on DOACs?
-
Jun 23, 2026, 17:33Maité Mulkers: Time is Brain, and One Reason is That a Thrombus Develops Over Time
-
Jun 23, 2026, 17:32Dhargam Aljebouri: Honoured to Be Part of the Young Professionals Breakfast at ISBT 2026
-
Jun 23, 2026, 17:27Dianne E. van der Wal: Phenotype and Activation of the Endothelium in ET at ISTH 2026